Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Key takeaways
- Recursion’s $200 million offering and Sanofi milestone payment strengthen its financial position and validate its drug‑development partnership.
- $200 million offering
- 61.54 million shares
- $3.25 per share
What happened
Recursion Pharmaceuticals (NASDAQ: RXRX) raised about $200 million in a new stock offering, pricing 61.54 million Class A shares at $3.25 each. The deal closed on Thursday after the bell, lifting the stock 0.24% to $4.17. Sanofi exercised an option on Recursion’s first development candidate, triggering a $10 million milestone payment and bringing total upfront and milestone payments from Sanofi to $144 million.
Why it matters
The fresh capital gives Recursion more runway for research and development, while the Sanofi milestone confirms progress on a promising inflammatory‑disease drug. The $144 million already received signals that the partnership is moving forward, and the company remains eligible for over $300 million more milestones…
Short-term and longer-term
Short-term. Over the next few days, watch for the final close of the offering and any immediate price reaction to the $144 million milestone.
Longer-term. In the coming months, the focus will shift to the drug’s development milestones and potential royalties.